Eronix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eronix

Understanding Eronix

Eronix is an oral medication categorized as an androgen receptor inhibitor. It is primarily utilized in the management of specific types of prostate cancer. The medication works by interfering with the biological processes that allow androgen hormones, such as testosterone, to promote the growth of cancer cells within the prostate gland.

Mechanism of Action

Prostate cancer cells often rely on androgens to grow and divide. Eronix is designed to block the effect of these hormones by binding to androgen receptors. By inhibiting this pathway, the medication helps to slow the progression of the disease and can aid in shrinking existing tumors or preventing the spread of malignant cells to other parts of the body.

Clinical Application

This treatment is typically indicated for adult men with prostate cancer that has either stopped responding to other hormonal therapies or has spread to other areas of the body. Because it targets the hormonal drivers of the disease, it is often part of a broader therapeutic strategy managed by oncology specialists. Unlike chemotherapy, which targets all rapidly dividing cells, Eronix specifically focuses on the androgen signaling pathway associated with prostate tumor biology.

What side effects are possible with Eronix?

Possible Side Effects and Safety Information

The officially documented safety profile for Eronix (Erythromycin) is structured around categories of adverse reactions and high-level safety constraints as established by government regulatory bodies.


Adverse Reaction Classification

Classification Category Details as Documented in Regulatory Sources
Common Gastrointestinal Disorders are the most frequently reported adverse reactions, affecting between 1% and 10% of patients. These include nausea, vomiting, abdominal pain/cramping, diarrhea, and anorexia.
Serious Adverse Reactions Clinically significant adverse effects include QT prolongation, which carries a documented risk of potentially fatal Torsade de pointes (a type of ventricular arrhythmia), and cholestatic hepatitis (liver toxicity). Severe skin reactions, such as Stevens-Johnson syndrome (SJS), are also listed.
System-Organ Classes Effects are classified across systems including Gastrointestinal Disorders, Cardiac Disorders, Hepatobiliary Disorders, and Nervous System Disorders.

Population-Specific and Safety Constraints

Specific safety considerations are noted for certain patient groups. For infants and neonates, a risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported following therapy. Older adults may be more susceptible to cardiac arrhythmias.

Eronix is contraindicated (absolutely restricted) in patients with a known history of QT prolongation, pre-existing ventricular cardiac arrhythmias, or uncorrected electrolyte imbalances (such as hypokalemia). This constraint is necessary due to the heightened risk of serious cardiac events. Furthermore, antibiotic-associated diarrhea is documented as a safety pattern that may occur even up to two months or more after discontinuation of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an Eronix overdose is structured around severe symptoms and the risk of critical complications, which mandate immediate medical intervention.


Overdose Scope: Officially Documented Manifestations

Domain Regulatory Documentation Summary
Documented Overdose Presentations Symptoms commonly include severe nausea, vomiting, and diarrhea following the ingestion of large quantities. Reversible hearing loss (ototoxicity) is also documented as a risk following high-dose exposure.
Physiological Systems Affected Overdose carries specific documented risks to the gastrointestinal, auditory, and cardiovascular systems.
Serious Outcomes Overdose may result in QTc interval prolongation and subsequent severe cardiac arrhythmia, including the life-threatening condition Torsades de Pointes.

Emergency Response and Management

Immediate actions are strictly mandated for any suspected overdose. The official prescribing information requires contacting a Poison Control Center and seeking immediate medical attention. Urgent medical help is required due to the documented potential for severe cardiac risks.

Management is limited to symptomatic and supportive treatment focused on maintaining vital functions, and may involve procedures like gastric lavage. Regulatory documentation specifies that no specific antidote is known for Erythromycin overdose, and the substance is not effectively removed by dialysis during treatment.

Therapeutic Uses of Eronix

What Eronix Treats: Main Uses and Benefits

Eronix, containing the macrolide antibiotic Erythromycin, is commonly used to manage active bacterial infections and generally is considered relevant as a therapeutic option when other treatments are unsuitable. Its use supports the body’s recovery by assisting with the management of the underlying infection. This medication is applied across several key therapeutic areas.

Management and Context

The primary therapeutic use of Eronix is in situations involving infections of the respiratory tract, such as certain types of pneumonia and pertussis (whooping cough); skin and soft tissue infections; and specific urogenital infections, including those caused by Chlamydia and Syphilis. This medication helps address symptom clusters related to heightened physiological activity, such as severe, persistent coughing and fever, and is used for managing the related symptomatic discomfort.

A relevant clinical scenario for Eronix is its use as an alternative treatment for patients with confirmed allergies or hypersensitivity to penicillin antibiotics. It is also applied in prophylactic situations, such as in situations supporting the reduced likelihood of rheumatic fever recurrence, or is applied in addressing the carrier state of certain communicable bacteria.

“Eronix provides support that helps ease the overall symptom burden and assists with maintaining functional stability during difficult episodes.”

This supportive role contributes to improved comfort during symptomatic periods.


QuickFact

Quick Fact Relief for Symptomatic Burden
Main Use Supports the management of bacterial infections, including those affecting the lungs, skin, and urogenital tract.
Key Benefit Contributes to easing the overall symptom load, such as severe cough and fever, and provides an alternative for penicillin-allergic patients.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eronix eligibility is strictly defined by regulatory agencies based on patient characteristics and concurrent medication use, establishing clear criteria for who may and must not use the medicine.

Contraindicated Populations

Use of Eronix is absolutely prohibited in patients with a known hypersensitivity to erythromycin or any macrolide antibiotic. It is also contraindicated in individuals with a history of QT prolongation (acquired or congenital) or ventricular cardiac arrhythmia. Furthermore, it must not be used concurrently with specific medications, including Cisapride, Pimozide, Astemizole, Terfenadine, Ergotamine, and certain statins like Lovastatin or Simvastatin.

Condition-Based and Age-Related Cautions

Population/Condition Eligibility Status (Regulatory Cautions)
Hepatic Impairment Use with caution due to the liver being the primary excretion route. Monitoring is required.
Electrolyte Disturbances Uncorrected hypokalemia or hypomagnesemia preclude use due to increased cardiac risk.
Infants (Neonates) Use in the first two weeks of life is associated with a risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Pregnancy/Lactation Use is permitted only if clearly needed, as determined by the prescribing authority.
Older Adults May be more susceptible to effects on the QT interval and hearing loss.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eronix's interaction profile is primarily defined by its documented role as a moderate inhibitor of the Cytochrome P450 3A4 ( CYP3A4) enzyme and an inhibitor of the P-glycoprotein ( P-gp) transporter. This dual action leads to increased plasma concentrations of many co-administered medications.

Contraindicated Combinations

Certain combinations are explicitly prohibited due to the risk of serious adverse events:

  • Statins: Lovastatin and Simvastatin (due to increased risk of myopathy, including rhabdomyolysis).
  • QT-prolonging agents: Terfenadine, Astemizole, Cisapride, and Pimozide (due to the risk of QTc prolongation and ventricular tachycardia).
  • Ergot Alkaloids: Ergotamine and Dihydroergotamine (due to the risk of acute ergot toxicity).

Clinically Significant Interactions

Co-administration with other CYP3A4 substrates may require monitoring due to the potential for increased systemic exposure. Examples include Oral Anticoagulants (e.g., Warfarin), Digoxin, Cyclosporine, and certain Calcium Channel Blockers (e.g., Verapamil, Diltiazem).

Co-administration with Theophylline is documented as potentially decreasing Eronix serum concentrations, which may result in a subtherapeutic effect.

Other Documented Interactions

Substance Category Interaction Constraint/Effect
Food Decreases absorption, necessitating a timing separation rule for administration.
Herbal Products St. John's Wort (as a CYP3A4 inducer) may decrease Eronix exposure.
Population Note Interaction severity, such as increased anticoagulant effects, is noted to be more pronounced in elderly patients.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Synthesis

This domain outlines the drug's primary action as an inhibitor by binding directly to the bacterial 50S ribosomal subunit and physically blocking the exit channel for nascent proteins. By arresting the elongation of polypeptide chains, this mechanism fundamentally stops the production of essential proteins required for cell growth and replication, resulting in the cessation of bacterial population growth.


️ Agonism and Modulation of Gastrointestinal Motility

This secondary domain describes the drug's interaction as an agonist with the motilin receptor in the human gastrointestinal tract, a target unrelated to its antimicrobial function. Activating this receptor promotes signaling that increases the contractility of smooth muscle in the stomach and small intestine, thereby accelerating gastric emptying and overall gastrointestinal transit.


️ Immunomodulation of Inflammatory Pathways

A distinct tertiary domain involves the drug's ability to act as a modulator of host immune responses, particularly by influencing the PI3K-delta/Akt signaling pathway. This modulation leads to a reduction in the release of certain pro-inflammatory mediators, which results in altered local immune and inflammatory activity within affected systems.

Dosage and Administration Information

How Eronix is Used: Official Administration Guidelines

Eronix (Erythromycin) administration is strictly defined by guidelines to ensure consistent usage patterns. The medicine is officially administered through three primary routes: Oral (as tablets, capsules, or suspension), Intravenous (IV) Infusion, and Topical (as gels or solutions). The choice of route depends on the specific context of use.


Administration Scope

Category Official Instruction
Dosing Schedule Standard adult maintenance is typically 250 mg every 6 hours or 500 mg every 12 hours (for base/stearate forms). The maximum dose for severe infections, via either oral or IV routes, is restricted to 4 g per day.
Timing in Relation to Meals Optimal absorption of some oral forms (base/stearate) is achieved when taken in a fasting state, generally 1/2 hour to 2 hours before meals. Other formulations, such as ethylsuccinate, may be taken without regard to food.
Age-Group Rules Pediatric dosing is weight-based, usually 30 to 50 mg/kg/day in equally divided doses. Dose adjustments are specified for adults with severe renal impairment; the total daily dose should not exceed 2 g in such cases.
Procedural Conditions IV Infusion must be administered slowly and intermittently, typically over 20 to 60 minutes, using the diluted solution. IV push is not an approved method. Delayed-release oral forms must not be crushed or chewed.

Official Course Duration

Usage patterns over time are regulated, particularly the minimum duration of therapy. For example, the treatment course for streptococcal infections must be maintained for a minimum of 10 days. IV therapy is intended for short-term use and should be transitioned to oral administration as soon as appropriate. These official instructions define a standardized protocol for the correct administration of the medicine, ensuring that procedural steps and timing constraints are followed.

Recent Clinical Evidence

Research Evidence Overview

This section summarizes the types of clinical studies and trials that have examined Eronix (Erythromycin), focusing on the structure of the evidence and the populations observed. This overview describes what researchers monitored and where data show patterns related to its use, but it does not provide clinical guidance or personal advice.


Evidence for Use in Acute Respiratory and Skin Infections

The research supporting the use of Eronix for conditions like Community-Acquired Pneumonia (CAP), Acute Bronchitis, and Skin and Soft Tissue Infections (SSTI) includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily examined clinical success metrics, focusing on measurements related to the resolution of fever or the status of lung infiltrates for CAP, and measurements related to the status of infection spread and inflammation for SSTI. For Acute Bronchitis, research exploring short-term symptom changes in unselected adults reported inconsistent measurements regarding the direct reduction of core respiratory symptoms, like cough, when compared to control groups.


Evidence for Use in Specific Bacterial and Alternative Therapies

Eronix was studied for specific conditions, including urogenital infections caused by susceptible bacteria and its role in prophylaxis following exposure to Pertussis (Whooping Cough). For urogenital infections, research consists of foundational clinical trials that measured outcomes related to systemic imbalance, such as metrics related to pathogen clearance. This evidence also describes its use in specific patient populations needing an alternative to penicillin.


Study Limitations and Research Gaps

Most of the available evidence concerning Eronix was studied for short-term and acute episodes of bacterial infections, and the follow-up durations in the primary trials were typically limited. Long-term effects are not fully established, and there is limited information regarding the durability of the reported effects. The evidence base includes a reliance on older studies, which may not fully reflect current, highly controlled trial standards. Research has described patterns related to bacterial resistance to Eronix, and this remains a topic of scientific monitoring. The certainty remains low regarding the consistency of measurements for conditions like Acute Bronchitis, and more research is ongoing to fully contextualize these symptom patterns.

Key Studies & References

  1. Erythromycin: MedlinePlus Drug Information - National Library of Medicine (NIH)
  2. Treatment of Community-Acquired Pneumonia in Adults: 2019 IDSA/ATS Clinical Practice Guidelines

Frequently Asked Questions (FAQ)

Common questions about Eronix (FAQ)

Q: Does Eronix treat the condition itself, or just the symptoms?

Official descriptions define Eronix as a bacteriostatic agent and protein synthesis inhibitor. Its primary purpose is to halt the growth of susceptible bacteria, which treats the underlying cause of the infection. Research has also examined measurements related to the resolution of fever or the status of infection spread.

Q: Can Eronix be taken by elderly people?

Regulatory documents state that use in older adults requires caution. This is because elderly patients may be more susceptible to the medicine's effects due to a greater frequency of decreased hepatic (liver) and cardiac (heart) function. Official product information notes that monitoring is typically required for patients in this group.

Q: Are there any supplements that might interact with Eronix?

Official interaction summaries specifically name the herbal product St. John's Wort as a substance that may decrease Eronix exposure in the body. Regulatory documents note that general supplements and herbal remedies are often not routinely tested for interactions, leading to a general advisory caution.

Q: Is it true that Eronix can be less effective over time?

Studies and official information indicate that patterns related to bacterial resistance to Eronix have been described. This means that, over time, specific bacterial strains may develop the ability to withstand the medicine’s action. The FDA label states that skipping doses or not completing the full course of therapy may increase the likelihood of bacteria developing resistance.

Q: Does Eronix cause weight changes?

The official safety profile documents several adverse effects that relate to the digestive system, including anorexia (loss of appetite), nausea, and diarrhea. While the most frequent side effects are gastrointestinal, some sources list weight loss as a reported adverse reaction. Official labeling notes the occurrence of anorexia.

Q: Is Eronix suitable for people with a history of mental health conditions?

The documented safety profile includes reactions across Nervous System Disorders. These effects include feelings of dizziness and somnolence (drowsiness). Though not a specific contraindication, official information notes adverse effects like irritability and, rarely, seizures or central nervous system damage.

Q: What is the main difference between Eronix and other medicines used for similar conditions?

Eronix (Erythromycin) is the first macrolide antibiotic discovered and is often reserved as an essential therapeutic alternative to penicillin. Compared to newer macrolides, it has a shorter half-life and is less stable in stomach acid. It is also described as having a documented potential for drug-drug interactions because of its action as a CYP450 inhibitor.

Q: How long does it take to start noticing any effect from Eronix?

Official patient information notes that it is common to feel better early in the course of therapy. However, regulatory documents do not specify an exact timeframe for the onset of effect. Official information emphasizes that the full course of therapy must be completed exactly as prescribed.

Q: Is Eronix available over the counter, or is a prescription always needed?

Eronix is formally classified as a prescription-only medicine. This means it is legally restricted and must be dispensed by a pharmacist with a valid prescription from a licensed healthcare provider.

Q: Are there any dietary restrictions I should be aware of while taking Eronix?

Official guidance notes that food generally decreases the absorption of the medicine, which is why some formulations are directed to be taken on an empty stomach. Official documents state that patients should avoid changing the amount of grapefruit or grapefruit juice consumed, as these can affect the levels of Eronix in the body.

Q: Is it normal to feel a certain symptom (general, non-specific) in the first week of taking Eronix?

Gastrointestinal disorders (nausea, abdominal pain, diarrhea) are the most frequently reported adverse reactions and are known to be dose-related. Liver injury has also been reported to occur with a short latency, typically one to three weeks after beginning therapy.

Q: What happens if I accidentally miss a dose of Eronix?

If a dose is missed, official patient information states it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. Official patient information states that a patient should not take double or extra doses to make up for the one missed.

Q: How long does Eronix stay in the system after the last dose?

The drug's active component has a relatively short half-life (the time it takes for the concentration to reduce by half) of about one to one and a half hours. However, official safety documentation notes that some adverse effects, such as antibiotic-associated diarrhea, may occur even up to two or more months after the last dose.

Q: Is it safe to drink alcohol while using Eronix?

Drug interaction databases classify the combination of Eronix and alcohol (ethanol) as a minor interaction. Official guidance states that consultation with a healthcare professional is recommended.

Q: What happens if Eronix is taken by someone who does not have the condition it treats?

The FDA label notes that prescribing Eronix in the absence of a proven or strongly suspected bacterial infection is considered unlikely to provide benefit. Furthermore, using the medicine in this way increases the risk of the development of drug-resistant bacteria.

Q: Do women and men experience Eronix differently?

Regulatory warnings for QT-interval prolongation (a change in the heart's electrical rhythm) are specifically noted to apply to all users, especially in women and those with existing cardiac risk factors. This adverse event carries a documented risk of potentially serious ventricular arrhythmia.

Q: Why do people say Eronix can cause sleep changes?

The official safety profile documents adverse effects on the Nervous System that may be related to sleep changes. These include documented effects such as somnolence (drowsiness) and dizziness, which could affect alertness and sleep patterns.

Q: What should I do if a side effect seems to be getting worse?

Official patient information advises that if symptoms do not improve within a few days, or if they become worse, patients are noted to check with their doctor. Similarly, specific severe reactions are noted to require immediate contact with a healthcare professional.

Q: How does Eronix affect the immune system?

Official descriptions define a secondary mechanism of action as a modulator of host immune responses, which is separate from its antibacterial effect. This action specifically involves influencing a signaling pathway that leads to a reduction in the release of certain pro-inflammatory mediators.

Q: Can Eronix be taken with cold and flu medication?

The label identifies interactions with many medications, including specific antihistamine and anti-sickness drugs sometimes found in cold and flu remedies, which may require caution. Due caution is noted, as is the general recommendation to inform a doctor or pharmacist about all other medicines being taken.

Q: Is it okay to drive or operate machinery while taking Eronix?

Regulatory documents state that due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery. This warning is in place because the medicine can cause documented side effects such as dizziness and somnolence (drowsiness).

Q: What information should I look for on the Eronix patient leaflet?

Patients should prioritize information regarding when and how to take the medicine exactly as directed, including the importance of completing the full course of therapy. It is also important to review the listed signs and symptoms of severe side effects, such as Clostridium difficile-associated diarrhea (CDAD).

Q: What happens if I stop taking Eronix suddenly?

The FDA label explicitly states that skipping doses or not completing the full course of therapy may decrease the effectiveness of the immediate treatment. More importantly, stopping treatment early can increase the likelihood of bacteria developing resistance.

Q: Are there any official registries or patient support programs for Eronix?

Official government drug agencies maintain systems for consumers to report side effects and adverse events directly, such as the FDA's MedWatch program. These systems allow regulatory bodies to continuously monitor and update the medicine's safety profile.

Q: Are there any specific groups of people where Eronix is known to be less effective?

Official interaction summaries indicate that co-administration with Theophylline is documented to potentially decrease Eronix serum concentrations. This effect may result in a subtherapeutic (less effective) outcome, which is noted to require careful monitoring.

Q: Why is Eronix sometimes described as a 'novel' treatment?

Eronix is classified as a Macrolide antibiotic. The active ingredient, Erythromycin, was the first macrolide discovered and has been in use since the 1950s. The term 'novel' is typically reserved for newer treatments, suggesting this description may be inaccurate and requiring clarification.

Q: Can Eronix affect the results of standard lab tests?

Official documents state that patients should inform their medical doctor that they are using Eronix before having any medical tests. Official safety information notes that the results of some lab tests may be affected by the medicine, such as the blood clotting time (Prothrombin Time/INR).

Q: Can the effectiveness of Eronix be affected by a person's age?

Official Age-Group Rules specify that pediatric dosing is weight-based and dose adjustments are needed for older adults with severe renal (kidney) impairment. These adjustments are required to ensure the patient achieves the correct therapeutic exposure to the medicine.

Q: What are the main benefits of choosing Eronix over older treatments?

Eronix is officially recognized for its utility as an essential therapeutic option for patients who have known sensitivities to other major antibiotic classes, such as penicillins. This distinction reflects its role in ensuring a therapeutic option remains available for patients with known sensitivities to other antibiotic classes.

Q: Have there been any recent updates to the official safety information for Eronix?

Official drug information portals maintained by regulatory bodies are continuously monitored and updated to reflect new safety data and patient information. Therefore, the information found on official government sites is dynamic and subject to ongoing review.

Q: What are the eligibility criteria for being prescribed Eronix?

Eligibility is strictly defined by conditions that preclude use, such as a known hypersensitivity to macrolides, a history of QT prolongation (a heart rhythm issue), or uncorrected electrolyte imbalances. Use in certain groups, like those with hepatic impairment (liver problems), requires caution and monitoring.

Q: Does Eronix have any known long-term effects that are not listed as side effects?

Studies and official information indicate that the evidence base primarily concerns short-term and acute episodes, and the follow-up durations in primary trials were typically limited. As a result, the full scope of any potential long-term effects is not fully established in regulatory documents.

How should Eronix be stored and disposed of?

How to Store and Dispose of Eronix

The official labeling for Eronix (Erythromycin) requires strict adherence to environmental controls for storage and handling. The medicine must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), depending on the formulation. It is mandatory to keep the product away from excessive heat, light, and moisture.

  • Handling: The medicine must not be frozen. Reconstituted oral suspension requires refrigeration and must be used within 10 days.
  • Packaging: Store the medicine in its original container, ensuring it is tightly closed.
  • Child Safety: All medicine must be kept out of the sight and reach of children.
  • Disposal: Expired or unused Eronix must be disposed of according to official FDA guidelines or by consulting a healthcare professional or local waste disposal service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eronix found in:

A-Z Index: